Sermorelin: what does the growth-hormone signal actually do?

What is the idea behind sermorelin?

Sermorelin resembles an active part of growth-hormone-releasing hormone (GHRH), a natural messenger that tells the pituitary gland beneath the brain to release growth hormone. Growth hormone can also influence IGF-1, another messenger. Sermorelin is a signal to release hormone, not the same thing as growth hormone itself. The signal matters only if the relevant system can respond; a higher blood measurement alone does not show better sleep, strength or health. Follow the growth-hormone story.1

Was Geref approved in the United States?

Yes, historically, for specific products and purposes. A Geref diagnostic preparation was approved in 1990 to assess the pituitary’s ability to release growth hormone. A separate preparation was approved in 1997 for children with idiopathic growth-hormone deficiency and growth failure. The manufacturer discontinued them, and their approvals were withdrawn in 2009. In 2013 the FDA determined they were not withdrawn for reasons of safety or effectiveness. That historical finding does not make a modern compounded or online product the former FDA-approved product, or establish an adult wellness indication.1

What did the children’s study actually measure?

In a 1996 open-label study, 110 previously untreated children with growth-hormone deficiency received GHRH(1–29); 86 were eligible for the efficacy analysis. Their average growth rate was reported as 4.1 cm per year before treatment, 8.0 at six months and 7.2 at 12 months. The study had no placebo group, and a change in growth rate in children with a diagnosed condition does not establish an effect on adult muscle, sleep or ageing. The numbers describe that study, not a prediction for a child.3

What happened in adults studying strength?

A six-week 1997 study followed 11 healthy older men given GHRH(1–29), with measurements before and after treatment. Night-time growth-hormone release increased; IGF-1 and measured body composition did not significantly change. Two of six strength measures and an endurance test improved. There was no untreated comparison group, so practice, chance and other changes cannot be ruled out as explanations; the study cannot establish that sermorelin causes muscle growth or greater strength.4

What about memory and sleep?

A 2006 randomised comparison assigned 100 healthy older adults to sermorelin or placebo for six months; 89 completed the study. Some cognitive-test results favoured sermorelin, an interesting finding that does not establish dementia prevention or a benefit for everyone. Earlier preliminary results from an ongoing study reported no improvement in a self-rated sleep score with sermorelin; those were not final objective sleep measurements. These different outcomes require different evidence. See sleep and focus and memory.56

Is it the same as tesamorelin or CJC-1295?

They are distinct peptides related to the GHRH signalling pathway, not interchangeable names. The US Egrifta WR product contains tesamorelin and has a particular indication for excess abdominal fat in adults with HIV-associated lipodystrophy; it is not labelled for general weight-loss management. CJC-1295 has different forms and naming issues. Compare the substances, products and evidence in the GHRH-family guide.78

What is known about harms and product quality?

The older studies were limited in size, population and duration. In the 2006 trial, one participant had an injection-site rash and another reported feeling unwell in events judged likely related to the study procedure; longer-term and uncommon risks are not established by these studies. A product’s route, ingredients, sterility and manufacturing matter. A past approval does not establish the quality or safety of a different formulation. For a reaction, see injection-site symptoms, and for product testing, what a certificate of analysis can show.51

The historical Geref diagnostic information also warned that medicines affecting pituitary hormone release, including insulin, glucocorticoids or somatostatin preparations, could affect the test response. That warning belongs to the former diagnostic product; it does not provide an interaction schedule for modern compounded or online sermorelin. Tell the prescribing team about medicines that affect hormones or blood sugar.2

What about competitive sport?

The 2026 World Anti-Doping Agency list names sermorelin among growth-hormone-releasing factors prohibited at all times for athletes covered by its rules. Check the applicable current list and the relevant anti-doping authority, including therapeutic-use requirements. The sport guide explains the checking process.9